Featured Articles

  1. Your Microbiome Might Be Trying To Tell You Something 12/22/2025

    Burnout is not an individual failure: it’s a systems imbalance, biologically and organizationally, write Tony Martignetti and Adela Bonoiu, Ph.D. 

  2. 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026 12/15/2025

    Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.

  3. There's A Big Misconception Around 'Inclusion,' And It's Holding Us Back 12/10/2025

    Inclusion is bigger than policy or workplace acronyms. It’s a way of living and fostering greater outcomes, writes Novo Nordisk's Jill Fallows Macaluso.

  4. Biotech Wasn't Ready For AI's Speed; Here's How We Catch Up 12/5/2025

    Computational success is no stand-in for therapeutic readiness. Innovators must learn to discern between models rooted in science and those that speculate.

  5. AI In Healthcare Comms: Enhancing Trust, Efficiency, And Compliance 12/5/2025

    Pharma and biotech companies can use AI to effectively and efficiently communicate with providers and patients, writes Jenna Phillips at PA Consulting.

  6. Corporate Spin-Offs And NewCos: Unlocking Value in Biopharma Innovation 12/2/2025

    Corporate spin-offs and NewCos can attract focused investment and accelerate innovation amid rising R&D costs, writes Joseph Pategou.

  7. Galien Forum: CEOs Talk FDA, China, Funding Sources 11/25/2025

    Part two of a two-part series covering FDA Commissioner Makary’s comments at the Galien Forum on October 30, plus coverage of a CEO roundtable on FDA, China, and funding.

  8. From Funding Gaps to AI Frontiers: Insights from the Boston Globe Summit 2025 11/20/2025

    Insights from the Boston Globe Summit 2025 exploring biotech funding challenges, AI-driven drug discovery, and genome editing breakthroughs shaping the future of research and care.

  9. Winning Strategies For Life Sciences In A Converging Policy Landscape 11/18/2025

    The simultaneous impacts of global trade shifts, U.S. tax reforms, and changing drug pricing policies have prompted life sciences companies to reevaluate their strategies, write experts at KPMG.

  10. Biotech Financing: Why Strong IP Is The Currency of Collaboration 11/11/2025

    Strong IP keeps collaboration alive, allowing companies to attract capital, strike partnerships, and bring innovations to patients, according to legal experts at Ice Miller.